cyrilzakka/clinical-trials huggingface dataset:
Low Level Laser Versus Polarized Light in the Treatment of Acne Vulgaris

The present study is designed to compare clinically the therapeutic applications between low level laser therapy (excimer laser) and non-laser polarized light (Bioptron prol) in the treatment of Acne vulgaris.

Traditional acne treatment often involves topical application, which can cause skin irritation and dryness, and oral antibiotic therapy, which is limited by antibiotic resistance. Newer procedures like laser and light-based therapies offer alternative treatments for patients who struggle with adherence or experience side effects or treatment failure. This study aims to compare the therapeutic application of laser and light therapies as an alternative to traditional acne treatments.

Eligibility Criteria:
Inclusion Criteria:

1. Female and male patients.
2. Age range between 18 and 25 years.
3. All patients will sign their informed consent to participate in the research procedure and to publish the data.
4. Definite clinical diagnosis of mild to moderate inflammatory lesions of facial Acne vulgaris (open and closed comedones, papules, pustules, and nodules) on the face that has been going on for at least 1 month.

Exclusion Criteria:

1. Patient's unwillingness to continue cooperation in the study
2. Photosensitive skin.
3. Pregnancy and breast feeding.
4. Women who use hormonal contraceptives.
5. Patients who had used oral retinoids or any other treatment for acne in the last month.
6. Patients with severe nodulocystic acne
Telemedicine for Optimized Collection of CLinical datA in Patients With Suspicion of Acute Stroke

Observational prospective single-center study on the discriminatory value of the Unassisted TeleStroke Scale for differentiation between patients with lacunar stroke and those with other acute stroke syndromes.

Assessment of stroke severity and differentiation between large-artery and small-artery stroke is pivotal for adequate treatment decision taking. Patients with small vessel stroke tend have a better prognosis than those with large artery disease. Further, patients with small artery infarction (lacunar stroke) have shown to respond well to treatment with intravenous recombinant tissue plasminogen activator (IV rt-PA), but are poor candidates for endovascular recanalization. Conversely, IV rt-PA may be less effective at restoring perfusion of large artery occlusion, a stroke subtype that may benefit from intra-arterial thrombolysis or embolectomy. Similarly, patients with large intracerebral hemorrhage or cerebellar hemorrhage may require neurosurgical interventions, such as intracranial pressure monitoring, ventricular drainage, surgical evacuation, or hemicraniectomy.

The purpose of TeleCLASS is to evaluate the discriminatory value of the Unassisted TeleStroke Scale (UTSS) obtained through in-hospital telemedicine for differentiation between patients with lacunar stroke and those with other acute stroke syndromes (nonLACS).

Eligibility Criteria:
Inclusion criteria:

* Age \> 18 years
* Suspicion of acute stroke with symptom onset \< 72 h before teleconsultation
* NIHSS score \> 0
* Informed consent

Exclusion criterion:

* Patients for whom telestroke consultation would delay any diagnostic or therapeutic intervention
To Assess Ear Blood Flow During Dialysis

This is a prospective observational pilot study of patients under the care of the Royal Free Hospital with chronic kidney disease who have been established on regular thrice weekly haemodialysis treatments in a dialysis centre,to measure the changes in blood flow in the ear during haemodialysis.

10 patients, attending for thrice weekly outpatient haemodiafiltration shall be studied during a dialysis session using a CE marked commercially available digital otoscope capable of recording digital videos of the tympanic membrane and ear canal.

Patients will receive standard clinical care and monitoring of their dialysis session, which includes recording of blood pressure and changes in haematocrit and volume status during dialysis and noting patient symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Patients age 18 years and older up to 80 years
* Under the care of the Royal Free Hospital with chronic kidney disease and established on regular thrice weekly haemodiafiltration.
* Able to provide written informed consent obtained

Exclusion Criteria:

* Patients unable to provide written informed consent
* Patients using hearing aids
* Patients who have had previous middle ear surgery
* Patients not fulfilling inclusion criteria
Usability of the CP950 Sound Processor

Studying usability and gaining feedback of the CP950 Sound Processor in experienced cochlear implant recipients.

One month protocol, with 2 study visits. The aim of the study to is to gain patient and audiologist feedback on their experience and usability with the device and wireless programming pod.

Eligibility Criteria:
Inclusion Criteria:

1. At least 6 months experience with a Nucleus 24 series or later implant in at least one implanted ear
2. Subjects age 12 and older who are cognitively and developmentally able to complete all study related questionnaires as deemed by the principal investigator or delegated staff
3. At least 3 months experience with the CP810,CP920 or CP910 sound processor
4. Ability to use 2 zinc air batteries with their current program (MAP)
5. Willingness to participate in and to comply with all requirements of the protocol for the duration of the trial

Exclusion criteria:

1. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and prosthetic device
2. Additional disabilities that would prevent participation in evaluations
3. Implant types not currently supported by the CP950 sound processor (i.e.,N22)
Diet Intervention in Food Sensitive Patients With IgA Nephropathy

The purpose of this study is to assess whether a tailored diet, eliminating antigens to which IgA nephropathy patients have demonstrated sensitivity, will have an effect on proteinuria, renal function and other immunological variables.


Eligibility Criteria:
Inclusion Criteria:

* Above 18 years
* IgA nephropathy (IgAN), verified by biopsy
* Proteinuria \> 1 g/24 h
* Having signed informed consent form

Exclusion Criteria:

* Participation in another clinical trial
* Patients with celiac disease
* Introduction of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARB) during the last three months prior to inclusion
* Patients treated with immunosuppressive or systemic corticosteroid drugs within the last twelve months
PictureRx: An Intervention to Reduce Latino Health Disparities (Supplement: Medical Icons)

Research shows that well-developed icons and other pictorials aid in the comprehension of medication information and are effective in improving patients' medication management. This experimental study seeks to test the effect of icons and structured medication information on subjects' processing and recall of simulated medication instructions in a computer testing environment. The study planned to enroll 200 subjects.


Eligibility Criteria:
Inclusion Criteria:

* Be at least 18 years old
* Fluency in English or Spanish
* Manage their own prescription medicines, and
* Be taking at least one chronic medication

Exclusion Criteria:

* Too ill to complete the experiment
* Having visual acuity worse than 20/50 via Rosenbaum Visual Acuity exam (eyechart)
* Inability to communicate in either Spanish or English
* Overt psychiatric illnesses, overt delirium or dementia
Automatic vs. Manual Optic Disc Planimetry

Manually and automatically by mashing learning algorithm optic disc will be evaluated (planimetry).

Cross-Over non-randomized Case-Series. Arm 1 (Manual segmentation): Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc. Arm 2 (Automated segmentation): Automatic detection of the boundaries of the optic disc and it's excavation. Calculation of cup size, size of excavation, cup-to-disc ratio, and rim area. Comparison of all parameters of both arms and computing of agreement.

Eligibility Criteria:
Inclusion Criteria:

* open-angle glaucoma

Exclusion Criteria:

* no fundus photography of the optic disc performed
Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke

Vascular endothelial growth factor (VEGF) and Endostatin (ES) participate angiogenesis after cerebral ischemia. Circulating endothelial progenitor cells (EPCs) also play a crucial role in neovascularization and tissue repair after acute ischemic stroke (AIS). The investigators sought to compare the expression of VEGF and ES in serum and the circulating EPCs in patients after AIS with that of healthy control subjects. The investigators obtained peripheral blood and serum samples from study subjects. EPCs in blood samples from AIS patients and healthy controls were quantified by flow cytometry 1 day, 3 days, 5 days and 7 days after AIS. VEGF and ES were measured by enzyme linked immunosorbent assay at the same time points. The relation between them and the relation of them to prognosis of such patients with acute ischemic stroke were assessed.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of acute ischemic stroke
* Admission within 12 hours
* National Institutes of Health Stroke Scale score 6-25

Exclusion Criteria:

* Lacunar infarction
* Cerebral hemorrhagic infarction
* Epilepsy or epileptic persons
* History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases
* Contraindications to antiplatelet treatments
* Died within the first week of hospitalization
* Serial blood samples could not be obtained
Comparison of an Electronic Version of Selected COPD PRO Instruments With the Original Versions

This protocol defines the requirements to demonstrate that the PRO instruments which were designed as paper-based are equivalent to the nSpire Health ePRO (electronic patient reported outcome), following the ISPOR's ePRO Good Research Practices Task Force recommendations. All validation studies of the questionnaires were conducted using the original paper versions.


Eligibility Criteria:
Inclusion Criteria:

* Give their signed written informed consent to participate
* Current symptoms COPD, as diagnosed by a physician
* Age 40 - 75 years
* Able to read and understand English

Exclusion Criteria:

• Unwilling to complete the 3 electronic PRO questionnaires or participate in an interview during completion of questionnaires
Effect of Implementing Snap-needle Therapy Combined With Ginger Paste During Anesthesia Recovery on the Recovery of Gastrointestinal Function After Gynecologic Laparoscopy

The aim of this study was to investigate the effect of implementing snap-needle therapy combined with ginger paste during anesthesia recovery on the recovery of gastrointestinal function after gynecological laparoscopy.


Eligibility Criteria:
Inclusion Criteria:

1. ASA I or II;
2. Performing gynecologic laparoscopic procedures under general anesthesia;

Exclusion Criteria:

1. Age ≤ 18 or ≥65;
2. The patient has a previous history of PONV, digestive disorders, etc;
3. Ulcers, infections, and skin tears at acupressure and acupuncture (snap-needle) treatment sites;
4. Patients allergic to ginger；
5. Inability to follow protocol or refusal to participant
Continuous Glucose Monitoring in Patients Undergoing Cardiopulmonary Bypass

The purpose of this research study is to test the accuracy of the Dexcom continuous glucose monitoring device during the cardiothoracic surgical procedure and recovery period in the Cardiac Intensive Care Unit. Readings from the device will be compared with the standard of care blood glucose levels that are obtained during your surgery and postoperatively.

The proposed study would examine 100 adult patients specifically undergoing cardiac surgical procedures with the explicit goal of comparing continuous glucose monitoring accuracy to point-of-care testing, particularly in the setting of physiologic perturbations due to vasopressors, acidosis, and hypothermia. With a large sample size and few stipulations on the included patients, this well-powered study would give broadly applicable guidance regarding continuous glucose monitoring use in this population. The study would establish a pathway to further research regarding optimizing continuous glucose monitoring accuracy, providing earlier detection of out-of-range glucose values, improving the precision of insulin titration, and ultimately improving glucose control in the cardiac surgical population, which may improve patient outcomes, including mortality. This would be the first study to describe intraoperative use of the newest Dexcom continuous glucose monitoring device, the G7, which has the shortest available warmup time and may be the most accurate continuous glucose monitoring device on the market.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Undergoing cardiac surgery with cardiopulmonary bypass at Atrium Health Wake Forest Baptist Medical Center

Exclusion criteria:

* Under 18 years of age
* Pregnant women
* Patients with a contraindication to device placement on the posterior arm, including rash, missing extremity, or existing line or device
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney disease (CKD) with secondary hyperparathyroidism who have vitamin D levels in the normal range. Previous studies with doxercalciferol were conducted in patients who had low levels of vitamin D.


Eligibility Criteria:
Inclusion Criteria:

* Plasma iPTH value above 110 pg/mL for CKD Stage 3 subjects or above 150 pg/mL for CKD Stage 4
* Serum 25-hydroxyvitamin D level greater than or equal to 30 ng/mL
* CKD Stage 3 evidenced by a glomerular filtration rate (GFR) from the abbreviated MDRD equation between 30-59 mL/min or CKD Stage 4 evidenced by a glomerular filtration rate (GFR) from the abbreviated MDRD equation between 15-29 mL/min

Exclusion Criteria:

* Serum cCa \> 9.5 mg/dL
* Serum P \> 4.6 mg/dL
* Abnormal liver functions
* Anticipated requirement for maintenance hemodialysis
* Use of active vitamin D sterol therapy
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio.

Data produced in this study will provide useful information regarding the value of P50 as an efficacy biomarker, and provide evidence for the optimal dosing of MEM 3454 for additional P50 studies.


Eligibility Criteria:
Inclusion Criteria:

* 1. Male or female subjects between 18and 55 years of age.
* 2. Fluent in English, even if English is not the primary language.
* 3. Able to provide informed consent.
* 4. DSM IV-R primary diagnosis of schizophrenia (any subtype), assessed using a structured diagnostic interview (SCID CT).
* 5. Few or no extra-pyramidal symptoms(EPS)at screening,defined as SAS \< 6.
* 6. Negative urine drug screen (UDS).
* 7. Negative cotinine test.
* 8. Clinically stable, as judged by the investigator, and in a non-acute phase for at least 12 weeks. At least one month on the same dose of antipsychotic medication.

Exclusion Criteria:

* Current risk of suicide, or history of suicidal behavior within the last 6 months.
* Hospitalized for psychiatric symptoms in the past 3 months.
* Other psychiatric diagnoses.
* Substance abuse/dependence (other than nicotine or caffeine) within the last 6 months according to the SCID-CT.
* Currently smoking, nicotine replacement therapy, smoking cessation medications or remedies, including Varenicline (Chantix).
* Any medical condition, as judged by the Investigator, which may interfere with the subjects' participation in this study.
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma

The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged 18-65 years.
* Asthma treated by inhaled SABA or inhaled SABA plus low-medium dose ICS in 6 weeks prior to randomisation.
* A reliable history consistent with moderate to severe rhinoconjunctivitis on exposure to ragweed for at least the previous two ragweed seasons.
* Positive skin prick test to ragweed
* Ragweed-specific Immunoglobulin E (IgE) ≥ 0.35 kU/L.

Exclusion Criteria:

* History of life-threatening asthma.
* Uncontrolled asthma according to GINA
* FEV1 of \< 70 % of predicted, regardless of the cause.
* Administration of adrenaline (epinephrine) is contraindicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension).
* History of severe drug allergy or anaphylactic reaction to food.
* A history of any significant disease or disorder (e.g. immune system, pulmonary, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment, history of alcohol or drug abuse)
Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers

The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of simvastatin 80 mg.


Eligibility Criteria:
Inclusion Criteria:

* Males and Females
* \>18 years of age
* Body weight 45 kg or greater

Exclusion Criteria:

* If female, of childbearing potential or lactation
* History of significant adverse reaction to any fibrate lipid-lowering agent or HMG-CoA reductase inhibitor
Optimizing Brain Stimulation Parameters

A primary purpose of this study is to better understand what stimulation parameters work best for patients. For example, for Deep Brain Stimulation (DBS) of the Anterior Nucleus of the Thalamus (ANT), it is not clear what stimulation frequency leads is most effective. This study will help assess the effectiveness of low frequency or high frequency stimulation.


Eligibility Criteria:
Inclusion Criteria:

* Patients who are implanted with a brain stimulation device targeting the anterior nucleus of the thalamus per Mayo Clinic standard of care

Exclusion Criteria:

* Patients for whom clinical follow-up is not expected during the initial 6-8 months following implant
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.


Eligibility Criteria:
Key Inclusion Criteria:

* Participants must have histologically confirmed prostate cancer.
* Radiographic evidence of metastatic disease, detectable by bone scan, CT scan, or MRI. At least one site of metastatic disease must be amenable to needle biopsy.
* Castrate levels of testosterone (testosterone \< 50 ng/dL) on androgen deprivation therapy (ADT). Patients who have not undergone orchiectomy will continue gonadotropin releasing hormone (GnRH) agonist or antagonist therapy.
* Age \> 18 years
* ECOG performance status \< 2
* Evidence of disease progression on ADT. Patients must have two serial rises in PSA from nadir, with at least 1 week between PSA measurements, with a minimum PSA of 2 ng/mL, OR patients must have radiographic evidence of progression. Nadir is defined as the lowest PSA value after beginning the most recent therapy for metastatic CRPC.

Key Exclusion Criteria:

* Participants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
* Participants may not be receiving any other study agents.
* Participants with known brain metastases
* Any history of seizure or a condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy).
* Concurrent therapy with medications known to have seizure potential (those must have been discontinued or substituted for at least 28 days prior to starting the trial)
* Concurrent treatment with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice) or inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort)
* History of pituitary dysfunction
* History of adrenal dysfunction
* Requirement for steroid use greater than 10 mg of prednisone daily
* History of gastrointestinal disorder or prior extensive gastrointestinal surgery that may interfere with sufficient absorption of the study compounds.
* Prior history of CYP17 inhibitors (e.g., abiraterone acetate, TAK-700) and second-generation anti-androgen (e.g., MDV3100)
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]TAS-303 following oral single dose


Eligibility Criteria:
Inclusion Criteria:

1. Healthy adult male subjects who provided written informed consent to participate in the study
2. Aged 18 years or older and younger than 40 years at the time of informed consent
3. Capable of oral intake.
4. Body weight of 50 kg or more and body mass index of 18.5 or more and less than 25.0
5. Had blood pressure, pulse rate, and body temperature meeting any of the following at screening:

Systolic blood pressure: ≧90 mmHg and ≦139 mmHg, Diastolic blood pressure: ≧40 mmHg and ≦89 mmHg, Pulse rate: ≧40 beats per minute (bpm) and ≦99 bpm, Body temperature: ≧35.0°C and ≦37.4°C

Exclusion Criteria:

1. Had current or previous hypersensitivity or allergy to drugs
2. Had current or previous drug abuse (including use of illicit drugs) or alcoholism
3. Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded)
4. Received a radioisotope-labeled substance or subject to a large quantity of radiation exposure\* within 12 months before the first dose of TAS-303.

   \* A large quantity of radiation exposure includes continuous X-ray irradiation, computed tomography (CT) scan, gastric barium test, and positron emission tomography (PET) scan, excluding tests with low radiation exposure (e.g., chest, bone, or dental X-ray examination, or X-ray examination before boarding an airplane).
5. Occupationally exposed to radiation within a year before the first dose of TAS-303 (such as operators who are involved in nuclear power or radiation operations).
Burn Scar Appearance After Treatment With Fractional Carbon Dioxide (CO2) Laser

The purpose of this study is to determine if fractional carbon dioxide laser treatment of a burn scar is a more effective method for improving the appearance of scars than the current available treatments.


Eligibility Criteria:
Inclusion Criteria:

* Have a mature burn scar and desire revision
* Fluent in English
* Must reside in the Los Angeles vicinity for the duration of the study

Exclusion Criteria:

* Previous history of scar revision
* Non-English speakers
* Pregnant or cognitively impaired subjects